Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 989560, 15 pages
http://dx.doi.org/10.1155/2015/989560
Research Article

Rapamycin Protects from Type-I Peritoneal Membrane Failure Inhibiting the Angiogenesis, Lymphangiogenesis, and Endo-MT

1Centro de Biología Molecular-Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas (CSIC), Cantoblanco, 28049 Madrid, Spain
2Departamento de Nefrologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, 05403-000 São Paulo, Brazil
3Aging and Inflammation Group, Instituto de Investigación Biomédica (INIBIC), 15006 A Coruña, Spain
4Departamento de Nefrología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), 28006 Madrid, Spain
5Departamento de Nefrología, Hospital Universitario La Paz & Instituto de Investigación Sanitaria la Paz (IdiPAZ), 28046 Madrid, Spain
6Departamento de Patología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), 28006 Madrid, Spain
7Unidad de Biología Molecular y Departamento de Nefrología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), 28006 Madrid, Spain

Received 23 May 2015; Revised 27 August 2015; Accepted 13 October 2015

Academic Editor: Janusz Witowski

Copyright © 2015 Guadalupe Tirma González-Mateo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. T. Krediet, B. Lindholm, and B. Rippe, “Pathophysiology of peritoneal membrane failure,” Peritoneal Dialysis International, vol. 20, supplement 4, pp. S22–S42, 2000. View at Google Scholar · View at Scopus
  2. P. J. Margetts and P. Bonniaud, “Basic mechanisms and clinical implications of peritoneal fibrosis,” Peritoneal Dialysis International, vol. 23, no. 6, pp. 530–541, 2003. View at Google Scholar · View at Scopus
  3. L. S. Aroeira, A. Aguilera, J. A. Sánchez-Tomero et al., “Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions,” Journal of the American Society of Nephrology, vol. 18, no. 7, pp. 2004–2013, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Yanez-Mo, E. Lara-Pezzi, R. Selgas et al., “Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells,” The New England Journal of Medicine, vol. 348, no. 5, pp. 403–413, 2003. View at Publisher · View at Google Scholar
  5. J. A. Jiménez-Heffernan, A. Aguilera, L. S. Aroeira et al., “Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis,” Virchows Archiv, vol. 444, no. 3, pp. 247–256, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. L. S. Aroeira, A. Aguilera, R. Selgas et al., “Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor,” American Journal of Kidney Diseases, vol. 46, no. 5, pp. 938–948, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Loureiro, A. Aguilera, R. Selgas et al., “Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage,” Journal of the American Society of Nephrology, vol. 22, no. 9, pp. 1682–1695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Gurzu, S. Turdean, A. Kovecsi et al., “Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: an update,” World Journal of Clinical Cases, vol. 3, no. 5, pp. 393–404, 2015. View at Publisher · View at Google Scholar
  9. S. Aoki, T. Takezawa, A. Oshikata-Miyazaki et al., “Epithelial-to-mesenchymal transition and slit function of mesothelial cells are regulated by the cross talk between mesothelial cells and endothelial cells,” American Journal of Physiology—Renal Physiology, vol. 306, no. 1, pp. F116–F122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. S. De Vriese, R. G. Tilton, C. C. Stephan, and N. H. Lameire, “Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane,” Journal of the American Society of Nephrology, vol. 12, no. 8, pp. 1734–1741, 2001. View at Google Scholar · View at Scopus
  11. W. Zheng, A. Aspelund, and K. Alitalo, “Lymphangiogenic factors, mechanisms, and applications,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 878–887, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Li, S. G. Kim, and J. Blenis, “Rapamycin: one drug, many effects,” Cell Metabolism, vol. 19, no. 3, pp. 373–379, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Boffa, F. Luan, D. Thomas et al., “Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer,” Clinical Cancer Research, vol. 10, no. 1, part 1, pp. 293–300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. N. S. Dejneka, A. M. Kuroki, J. Fosnot, W. Tang, M. J. Tolentino, and J. Bennett, “Systemic rapamycin inhibits retinal and choroidal neovascularization in mice,” Molecular Vision, vol. 10, pp. 964–972, 2004. View at Google Scholar · View at Scopus
  15. Y. S. Kwon, H. S. Hong, J. C. Kim, J. S. Shin, and Y. Son, “Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo,” Investigative Ophthalmology and Visual Science, vol. 46, no. 2, pp. 454–460, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Lieberthal and J. S. Levine, “The role of the mammalian target of rapamycin (mTOR) in renal disease,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2493–2502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Xu, J. Y. Xie, W. M. Wang, H. Ren, and N. Chen, “Impact of rapamycin on peritoneal fibrosis and transport function,” Blood Purification, vol. 34, no. 1, pp. 48–57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Ceri, S. Unverdi, M. Dogan et al., “Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model,” International Urology and Nephrology, vol. 44, no. 3, pp. 977–982, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. G. T. González-Mateo, J. Loureiro, J. A. Jiménez-Hefferman et al., “Chronic exposure of mouse peritoneum to peritoneal dialysis fluid: structural and functional alterations of the peritoneal membrane,” Peritoneal Dialysis International, vol. 29, no. 2, pp. 227–230, 2009. View at Google Scholar · View at Scopus
  20. J. Loureiro, P. Sandoval, G. del Peso et al., “Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis,” PLoS ONE, vol. 8, no. 4, Article ID e61165, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. López-Cabrera, A. Aguilera, L. S. Aroeira et al., “Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure,” Peritoneal Dialysis International, vol. 26, no. 1, pp. 26–34, 2006. View at Google Scholar · View at Scopus
  22. A. W. D. Stavenuiter, M. N. Schilte, P. M. Ter Wee, and R. H. J. Beelen, “Angiogenesis in peritoneal dialysis,” Kidney and Blood Pressure Research, vol. 34, no. 4, pp. 245–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. Q. Xue, J. A. Nagy, E. J. Manseau, T. L. Phung, H. F. Dvorak, and L. E. Benjamin, “Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 8, pp. 1172–1178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Kinashi, Y. Ito, M. Mizuno et al., “TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis,” Journal of the American Society of Nephrology, vol. 24, no. 10, pp. 1627–1642, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Morelle, A. Sow, N. Hautem et al., “Interstitial fibrosis restricts osmotic water transport in encapsulating peritoneal sclerosis,” Journal of the American Society of Nephrology, vol. 26, no. 10, pp. 2521–2533, 2015. View at Publisher · View at Google Scholar
  26. P. Patel, Y. Sekiguchi, K.-H. Oh, S. E. Patterson, M. R. J. Kolb, and P. J. Margetts, “Smad3-dependent and-independent pathways are involved in peritoneal membrane injury,” Kidney International, vol. 77, no. 4, pp. 319–328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Aguilera, L. S. Aroeira, M. Ramírez-Huesca et al., “Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells,” International Journal of Artificial Organs, vol. 28, no. 2, pp. 164–169, 2005. View at Google Scholar · View at Scopus
  28. S. Huber, C. J. Bruns, G. Schmid et al., “Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis,” Kidney International, vol. 71, no. 8, pp. 771–777, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Garosi, N. Mancianti, R. Corciulo, V. La Milia, and G. Virga, “Encapsulating peritoneal sclerosis,” Journal of Nephrology, vol. 21, pp. 177–187, 2013. View at Publisher · View at Google Scholar
  30. A. Aguilera, M. Yáñez-Mo, R. Selgas, F. Sánchez-Madrid, and M. López-Cabrera, “Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients,” Current Opinion in Investigational Drugs, vol. 6, no. 3, pp. 262–268, 2005. View at Google Scholar · View at Scopus
  31. M. R. Korte, M. W. Fieren, D. E. Sampimon, H. F. Lingsma, W. Weimar, and M. G. H. Betjes, “Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS study,” Nephrology Dialysis Transplantation, vol. 26, no. 2, pp. 691–697, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. G. M. Frascà, M. D’Arezzo, A. M. Ricciatti et al., “m-TOR inhibitors may be useful in the treatment of encapsulating peritoneal sclerosis (EPS),” Journal of Nephrology, vol. 27, no. 5, pp. 587–590, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Chatterjee, S. Mukhopadhyay, K. Tung, D. Patel, and D. A. Foster, “Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways,” Cancer Letters, vol. 360, no. 2, pp. 134–140, 2015. View at Publisher · View at Google Scholar
  34. D. C. Fingar and J. Blenis, “Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression,” Oncogene, vol. 23, no. 18, pp. 3151–3171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Tulek, E. Kiyan, H. Toy, A. Kiyici, C. Narin, and M. Suerdem, “Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycininduced pulmonary fibrosis in rats,” Clinical and Investigative Medicine, vol. 34, no. 6, pp. E341–E348, 2011. View at Google Scholar · View at Scopus
  36. P. Bonniaud, P. J. Margetts, K. Ask, K. Flanders, J. Gauldie, and M. Kolb, “TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis,” The Journal of Immunology, vol. 175, no. 8, pp. 5390–5395, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. A. N. Kothari, Z. Mi, M. Zapf, and P. C. Kuo, “Novel clinical therapeutics targeting the epithelial to mesenchymal transition,” Clinical and Translational Medicine, vol. 3, article 35, 2014. View at Publisher · View at Google Scholar
  38. S. Lamouille and R. Derynck, “Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-beta-induced epithelial-mesenchymal transition,” Cells Tissues Organs, vol. 193, no. 1-2, pp. 8–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Lamouille and R. Derynck, “Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway,” Journal of Cell Biology, vol. 178, no. 3, pp. 437–451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Gao, J. Zhang, T. Liu, and W. Shi, “Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study,” Molecular Vision, vol. 17, pp. 3406–3414, 2011. View at Google Scholar · View at Scopus
  41. Y. Sekiguchi, J. Zhang, S. Patterson et al., “Rapamycin inhibits transforming growth factor beta-induced peritoneal angiogenesis by blocking the secondary hypoxic response,” Journal of Cellular and Molecular Medicine, vol. 16, no. 8, pp. 1934–1945, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. W. Yu, Z. Liu, S. An et al., “The endothelial-mesenchymal transition (EndMT) and tissue regeneration,” Current Stem Cell Research & Therapy, vol. 9, no. 3, pp. 196–204, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. W. Zhang, G. Chen, J.-G. Ren, and Y.-F. Zhao, “Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations,” British Journal of Pharmacology, vol. 170, no. 6, pp. 1210–1220, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Braun, M. D. Alscher, P. Fritz et al., “The spectrum of podoplanin expression in encapsulating peritoneal sclerosis,” PLoS ONE, vol. 7, no. 12, Article ID e53382, p. 31, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Stachowska-Pietka, J. Waniewski, M. F. Flessner, and B. Lindholm, “Distributed model of peritoneal fluid absorption,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 291, no. 4, pp. H1862–H1874, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Morelle, A. Sow, D. Vertommen, F. Jamar, B. Rippe, and O. Devuyst, “Quantification of osmotic water transport in vivo using fluorescent albumin,” The American Journal of Physiology—Renal Physiology, vol. 307, no. 8, pp. F981–F989, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Luo, L. Liu, D. Rogers et al., “Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression,” Neoplasia, vol. 14, no. 3, pp. 228–237, 2012. View at Publisher · View at Google Scholar · View at Scopus